Logo for Karyopharm Main Menu Corporate Governance The Board of Directors of Karyopharm Therapeutics (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations. Committee Charters Title Documents Audit Committee Charter Commercialization and Portfolio Committee Compensation Committee Charter Nominating, Corporate Governance and Compliance Committee Charter Corporate Documents Title Documents Code of Ethics and Business Conduct Notice of Amendment to Code of Ethics and Business Conduct Corporate Governance Guidelines Hotline Information California Annual Declaration of Compliance © Karyopharm, 2020. All Rights Reserved. Terms of Use Privacy Policy Site Map

Logo for Karyopharm Main Menu Financial Information > Key Ratios Key Ratios NASDAQKPTI Price & Volume Recent Price $7.11 52 Week High $18.00 52 Week Low $4.42 Average Volume (30 days) 2.30M Beta 0.07 Share Related Items Market Cap $581.72M Shares Outstanding 75.55M Float 71.79M Dividend Information Yield % -- Annual Dividend -- Payout Ratio -36.8% Financial Strength Quick Ratio (MRQ) 3.2 Current Ratio (MRQ) 3.5 LT Debt/Capital (MRQ) 72% Total Debt/Equity (MRQ) 259% Valuation Ratios Price/Earnings (TTM) (2.80) Price/Sales (TTM) 4.90 Price/Book (MRQ) 12.05 Price/Cash Flow (TTM) -- Per Share Data Earnings (TTM) ($2.75) Sales (TTM) $1.57 Book Value (MRQ) ($1.67) Cash Flow (TTM) ($2.18) Cash (MRQ) $2.71 Management Effectiveness Return on Equity (TTM) 977.2% Return on Assets (TTM) -69.7% Return on Investment (TTM) -109.3% Profitability Gross Margin (TTM) 96.9% EBIT Margin (TTM) -152.2% Profit Margin (TTM) -- Currency in USD. Quote data delayed by at least 15 minutes. © Karyopharm, 2020. All Rights Reserved. Terms of Use Privacy Policy Site Map

Logo for Karyopharm Main Menu Financial Information > Annual Reports & Proxy Statements Annual Reports & Proxy Statements Form 10-Ks Filing Date View Feb 24, 2021 Feb 26, 2020 Feb 28, 2019 Mar 15, 2018 Mar 16, 2017 Mar 15, 2016 Mar 13, 2015 Mar 21, 2014 Proxy Statements Filing Date View May 3, 2021 Apr 7, 2021 Apr 7, 2021 Apr 9, 2020 Apr 9, 2020 Apr 19, 2019 Apr 19, 2019 Apr 2, 2019 Apr 27, 2018 Apr 27, 2018 Apr 28, 2017 Apr 29, 2016 Apr 7, 2015 Apr 28, 2014 © Karyopharm, 2020. All Rights Reserved. Terms of Use Privacy Policy Site Map